A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16319 ↗At a glance
Journal article in Internal Medicine Journal, 2024. Written by Michael V Brown and 6 co-authors. Institution: Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Major MEDLINE topics: Pulmonary Emphysema, Pneumonectomy. Cited 3 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Endobronchial valve (EBV) insertion for lung volume reduction is a management option for patients with severe emphysema. One‐way valves cause lobar deflation and improve lung function, exercise capacity and quality of life.
Aims
To retrospectively analyse and compare the outcomes of the first 57 patients treated with EBVs between 2015 and 2021 at the Royal Adelaide Hospital to international standards.
Methods
Clinical outcomes of forced expiratory volume in 1 s (FEV1), residual volume (RV), treated lobe volume reduction (TLVR) and 6‐min walk distance (6MWD) at 3, 6 and 12 months after valve insertion were reviewed against established minimally clinically important differences (MCIDs). Complications and subjective breathlessness measured by Borg scores were also reviewed.
Results
Fifty‐seven patients were included. At 12 months, 77.2% achieved TLVR. FEV1 improved by 170 mL (95% confidence interval (CI): 100–250, P < 0.001), 80 mL (95% CI: 10–150, P = 0.019) and 40 mL (95% CI: −60 to 130, P 0.66) at 3, 6 and 12 months respectively. RV improved by −610 mL (95% CI: −330 to −900, P < 0.0001) at 3 months, −640 mL (95% CI: −360 to −920, P < 0.0001) at 6 months and −360 mL (95% CI: −60 to −680, P = 0.017) at 12 months. 6MWD improved by 57.34 m (95% CI: 36.23–78.45, P < 0.0001) and 44.93 m (95% CI: 7.19–82.67, P = 0.02) at 3 and 6 months. Borg score improved by −0.53 (95% CI: 0.11 to −1.2, P = 0.11) and −0.49 (95% CI: 0.17 to −1.15, P = 0.16) at 3 and 6 months. Complication rates aligned with international standards with mucous/infection (26.3%) and pneumothorax (17.5%) as the most common. Subgroup analysis signalled improved outcomes in patients with heterogeneous emphysema.
Conclusion
Our study represents the first publicly funded Australian analysis of EBVs. The results align with international prospective trials demonstrating improved lung function and exercise capacity. Australians with severe emphysema and gas trapping should be referred to a multidisciplinary centre for consideration of EBVs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Faculty of Health and Medical Sciences, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
- Department of Respiratory and Sleep Medicine, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
- Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- SA Medical Imaging, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
ORCID profiles: Michael V Brown
Cite
APA
Brown, M. V., Badiei, A., Jersmann, H., Fon, A., Chew, C. G., Lorraine, B., & Nguyen, P. (2024). A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort. Internal Medicine Journal. https://doi.org/10.1111/imj.16319
Vancouver
Brown MV, Badiei A, Jersmann H, Fon A, Chew CG, Lorraine B, et al. A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort. Internal Medicine Journal. 2024. doi:10.1111/imj.16319
BibTeX
@article{Brown2024,
author = {Brown, Michael V and Badiei, Arash and Jersmann, Hubertus and Fon, Andrew and Chew, Chong G and Lorraine, Brett and Nguyen, Phan},
title = {A 6‐year experience of Zephyr endobronchial valves for severe emphysema in an Australian single‐centre cohort},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16319}
}
EUVIMED